160 related articles for article (PubMed ID: 5093780)
1. Functional relationship of factor B in the properdin system to C3 proactivator of human serum.
Goodkofsky I; Lepow IH
J Immunol; 1971 Oct; 107(4):1200-4. PubMed ID: 5093780
[No Abstract] [Full Text] [Related]
2. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
3. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
[TBL] [Abstract][Full Text] [Related]
4. The role of properdin in the alternate pathway of complement activation.
Götze O; Müller-Eberhard HJ
J Exp Med; 1974 Jan; 139(1):44-57. PubMed ID: 4808709
[TBL] [Abstract][Full Text] [Related]
5. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
6. A properdin system intermediate formed by zymosan and serum at 0 degrees C.
Yukiyama Y; Lew FT; Waks HS; Osler AG
J Immunol; 1976 Jan; 116(1):188-93. PubMed ID: 812914
[TBL] [Abstract][Full Text] [Related]
7. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
8. Inhibitor of human C3 associated with preparations of C3 dissociated from C3-zymosan complex.
Blum L
J Immunol; 1969 Nov; 103(5):1116-24. PubMed ID: 5350971
[No Abstract] [Full Text] [Related]
9. Detection of bound C3 by a new immunochemical methods.
Borsos T; Leonard EJ
J Immunol; 1971 Sep; 107(3):766-71. PubMed ID: 5315244
[No Abstract] [Full Text] [Related]
10. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
Brade V; Nicholson A; Bitter-Suermann D; Hadding U
J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
[No Abstract] [Full Text] [Related]
11. Agglutination of complement-coated erythrocytes by serum amyloid P-component.
Hutchcraft CL; Gewurz H; Hansen B; Dyck RF; Pepys MB
J Immunol; 1981 Mar; 126(3):1217-9. PubMed ID: 7462631
[TBL] [Abstract][Full Text] [Related]
12. Proceedings: Cleavage of the third complement component (C3) and release of a spasmogenic, C3-derived peptide (C3a) by epsilon-aminocaproic acid (EACA) in serum: a process involving the complement activating properdin system.
Vogt W; Schmidt G
Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R103. PubMed ID: 4276668
[No Abstract] [Full Text] [Related]
13. Some observations on the properdin system. 8. Properdin and its relation to blood constituents of human and some laboratory animals.
Majumdar AC; Datta TK; Sarma AK; Ray MK
J Indian Med Assoc; 1972 Nov; 59(10):428-31. PubMed ID: 4658784
[No Abstract] [Full Text] [Related]
14. Inhibition by cinnarizine of the properdin-dependent activation of complement.
Di Perri T; Auteri A; Pasini FL; Mattioli F
Arch Int Pharmacodyn Ther; 1977 Apr; 226(2):281-5. PubMed ID: 879911
[TBL] [Abstract][Full Text] [Related]
15. Blocking of the hemolytic expression of the classical complement sequence by products of complement activation via the alternate pathway. Materials responsible for the blocking phenomenon and their proposed mechanism of action.
Koethe SM; Austen KF; Gigli I
J Immunol; 1973 Feb; 110(2):390-400. PubMed ID: 4684033
[No Abstract] [Full Text] [Related]
16. Complement as a mediator of inflammation in acute gouty arthritis. I. Studies on the reaction between human serum complement and sodium urate crystals.
Naff GB; Byers PH
J Lab Clin Med; 1973 May; 81(5):747-60. PubMed ID: 4349137
[No Abstract] [Full Text] [Related]
17. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
Brade V; Nicholson A; Lee GD; Mayer MM
J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
[No Abstract] [Full Text] [Related]
18. Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan.
Brade V; Vogt W
Eur J Immunol; 1971 Aug; 1(4):295-300. PubMed ID: 4945686
[No Abstract] [Full Text] [Related]
19. Partial properdin deficiency.
Davis CA; Forristal J
J Lab Clin Med; 1980 Oct; 96(4):633-9. PubMed ID: 6903190
[TBL] [Abstract][Full Text] [Related]
20. Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis.
Tsao N; Tsai WH; Lin YS; Chuang WJ; Wang CH; Kuo CF
Biochem Biophys Res Commun; 2006 Jan; 339(3):779-84. PubMed ID: 16329996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
